Association of androgen receptor, prostate-specific antigen, and cyp19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 835-840

  Soni, Abha ^a   Bansal, Anju ^a   Mishra, Ashwani Kumar ^a   Batra, Jyotsna ^b   Singh, Laishram Chandreshwor ^a   Chakraborty, Anurupa ^a   Yadav, Dhirendra Singh ^a   Mohanty, Nayan K ^a   Saxena, Sunita ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CAG REPEAT; CANCER RISK; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AROMATASE; CASE-CONTROL STUDIES; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 84865675188     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0322     Document Type: Article

References (35)

1. Balic I, Graham ST, Troyer DA, et al. (2002) Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 168:2245-2248.
2. Blin N, Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3:2303-2308.
3. Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207-223.
4. Chiang CH, Chen KK, Chang LS, Hong CJ (2004) The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol 171:1529-1532.
5. Cussenot O, Azzouzi AR, Nicolaiew N, et al. (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25:3596-3602.
6. dos Santos RM, de Jesus CM, Trindade Filho JC, et al. (2008) PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol 27:497-503.
7. Ellem SJ, Risbridger GP (2007) Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 7:621-627.
8. Ellem SJ, Schmitt JF, Pedersen JS, et al. (2004) Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 89:2434-2441.
9. Erbersdobler A, Isbarn H, Dix K, et al. (2010) Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28:687-692.
10. Feldman D (1997) Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst 89:109-111.
11. Gsur A, Preyer M, Haidinger G, et al. (2002) Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23:1647-1651.
12. Gu M, Dong X, Zhang X, Niu W (2012) The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis. Mol Biol Rep 39:2615-2624.
13. Guy M, Kote-Jarai Z, Giles GG, et al. (2009) Identification of new genetic risk factors for prostate cancer. Asian J Androl 11:49-55.
14. Haiman CA, Hankinson SE, Spiegelman D, et al. (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87:204-210.
15. Hammoud AO, Griffin J, Meikle AW, et al. (2010) Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration. Hum Reprod 25:3146-3151.
16. Jariwala U, Prescott J, Jia L, et al. (2007) Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 6:39.
17. Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
18. Krishnaswamy V, Kumarasamy T, Venkatesan V, et al. (2006) South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet 51:254-257.
19. Lai J, Kedda MA, Hinze K, et al. (2007) PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28:1032-1039.
20. Latil A, Bieche I, Vidaud D, et al. (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61:1919-1926.
21. Mishra D, Thangaraj K, Mandhani A, et al. (2005) Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? Clin Genet 68:55-60.
22. Mittal RD, Mishra DK, Thangaraj K, et al. (2007) Is there an interrelationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? Steroids 72:335-341.
23. Modugno F, Weissfeld JL, Trump DL, et al. (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092-3096.
24. Rao A, Chang BL, Hawkins G, et al. (2003) Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 61:864-869.
25. Rodriguez-Gonzalez G, Cabrera S, Ramirez-Moreno R, et al. (2009) Short alleles of both GGN and CAG repeats at the exon-1 of the androgen receptor gene are associated to increased PSA staining and a higher Gleason score in human prostatic cancer. J Steroid Biochem Mol Biol 113:85-91.
26. Salinas CA, Austin MA, Ostrander EO, Stanford JL (2005) Polymorphisms in the androgen receptor and the prostatespecific antigen genes and prostate cancer risk. Prostate 65:58-65.
27. Santos ML, Sarkis AS, Nishimoto IN, Nagai MA (2003) Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detect Prev 27:321-326.
28. Satyanarayana L, Asthana S (2008) Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. Indian J Med Sci 62:35-44.
29. Schatzl G, Marberger M, Remzi M, et al. (2005) Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology 65:1141-1145.
30. Scher HI, Buchanan G, Gerald W, et al. (2004) Targeting the androgen receptor: improving outcomes for castrationresistant prostate cancer. Endocr Relat Cancer 11:459-476.
31. Sinha R, Anderson DE, McDonald SS, Greenwald P (2003) Cancer risk and diet in India. J Postgrad Med 49:222-228.
32. Soni A, Bansal A, Singh LC, et al. (2011) Gene expression profile and mutational analysis of DNA mismatch repair genes in carcinoma prostate in Indian population. OMICS 15:319-324.
33. Tsuchiya N, Wang L, Suzuki H, et al. (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-1989.
34. Xue W, Irvine RA, Yu MC, et al. (2000) Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60:839-841.
35. Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H (2004) How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 13:1765-1771